2/27/2007 3:08:35 PM
Antibody therapeutics company EvoGenix Limited (ASX:EGX) and Melbourne-based biotechnology company Vegenics Limited (65% owned by Circadian Technologies Limited ASX:CIR) today announced that they had entered into a Technology Collaboration agreement. EvoGenix will apply its proprietary technologies for antibody humanisation and optimisation to assist Vegenics in developing an antibody therapeutic product targeting VEGF-D. The collaboration is designed to generate a superior antibody that can safely enter trials in patients.
comments powered by